Wall Street analysts forecast that Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) will announce sales of $5.45 million for the current quarter, Zacks reports. Four analysts have provided estimates for Arrowhead Pharmaceuticals’ earnings. The highest sales estimate is $10.60 million and the lowest is $500,000.00. Arrowhead Pharmaceuticals posted sales of $8.71 million during the same quarter last year, which suggests a negative year-over-year growth rate of 37.4%. The firm is expected to announce its next quarterly earnings report on Tuesday, December 11th.

According to Zacks, analysts expect that Arrowhead Pharmaceuticals will report full year sales of $12.17 million for the current financial year, with estimates ranging from $5.40 million to $16.00 million. For the next financial year, analysts expect that the business will post sales of $35.10 million per share, with estimates ranging from $200,000.00 to $109.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.01. Arrowhead Pharmaceuticals had a negative net margin of 400.13% and a negative return on equity of 59.39%. The firm had revenue of $0.73 million during the quarter, compared to analyst estimates of $0.62 million.

Several equities research analysts recently weighed in on the stock. BidaskClub raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 15th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, August 8th. ValuEngine raised shares of Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Jefferies Financial Group reissued a “buy” rating and set a $20.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, August 8th. Finally, Piper Jaffray Companies raised their price target on shares of Arrowhead Pharmaceuticals to $11.00 and gave the company an “overweight” rating in a research report on Tuesday, May 8th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Arrowhead Pharmaceuticals has an average rating of “Buy” and an average target price of $16.20.

Shares of ARWR traded up $0.05 on Tuesday, hitting $14.38. 110,905 shares of the stock traded hands, compared to its average volume of 1,836,468. The company has a market capitalization of $1.49 billion, a P/E ratio of -30.38 and a beta of 1.85. The company has a quick ratio of 8.69, a current ratio of 8.69 and a debt-to-equity ratio of 0.02. Arrowhead Pharmaceuticals has a one year low of $1.90 and a one year high of $17.50.

In other Arrowhead Pharmaceuticals news, CFO Kenneth Allen Myszkowski sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, June 19th. The shares were sold at an average price of $14.01, for a total value of $280,200.00. Following the completion of the sale, the chief financial officer now owns 330,815 shares of the company’s stock, valued at approximately $4,634,718.15. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 4.60% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. RTW Investments LP grew its position in Arrowhead Pharmaceuticals by 184.6% in the 2nd quarter. RTW Investments LP now owns 8,299,542 shares of the biotechnology company’s stock worth $112,874,000 after purchasing an additional 5,382,981 shares during the period. OppenheimerFunds Inc. grew its position in Arrowhead Pharmaceuticals by 23.9% in the 1st quarter. OppenheimerFunds Inc. now owns 7,807,644 shares of the biotechnology company’s stock worth $56,293,000 after purchasing an additional 1,507,644 shares during the period. BlackRock Inc. grew its position in Arrowhead Pharmaceuticals by 108.1% in the 2nd quarter. BlackRock Inc. now owns 7,083,926 shares of the biotechnology company’s stock worth $96,342,000 after purchasing an additional 3,679,986 shares during the period. Acuta Capital Partners LLC bought a new stake in Arrowhead Pharmaceuticals in the 1st quarter worth approximately $12,706,000. Finally, Nexthera Capital LP bought a new stake in Arrowhead Pharmaceuticals in the 1st quarter worth approximately $8,033,000. 47.20% of the stock is owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target.

Featured Story: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Arrowhead Pharmaceuticals (ARWR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.